Document is current
Any future updates will be listed below
-
Authors
Luckett, Patrick H. https://orcid.org/0000-0003-2262-6605
Olufawo, Michael O.
Park, Ki Yun
Lamichhane, Bidhan
Dierker, Donna
Verastegui, Gabriel Trevino
Lee, John J.
Yang, Peter
Kim, Albert
Butt, Omar H.
Chheda, Milan G.
Snyder, Abraham Z.
Shimony, Joshua S.
Leuthardt, Eric C.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA203861, R01CA203861)
National Institute of Neurological Disorders and Stroke (U24NS109103, U24NS109103)
National Institute of Biomedical Imaging and Bioengineering (P41EB018783)
- License Information
-
More Information
Article History
Received: 15 April 2024
Accepted: 14 May 2024
First Online: 24 May 2024
Declarations
:
: This study was approved by the Washington University in St. Louis Institutional Review Board (IRB# 202306027). The requirement for informed consent for this retrospective study was waived by the IRB. This manuscript contains no individual person’s data in any form.
: Patrick Luckett, Joshua Shimony, Eric Leuthardt, Ki Yun Park, Abraham Snyder, and/or Washington University in St. Louis may receive royalty income based on a technology developed by Patrick Luckett, Joshua Shimony, Eric Leuthardt, Abraham Snyder, and Ki Yun Park and licensed by Washington University to Sora Neuroscience. Eric Leuthardt owns stock in Neurolutions, General Sensing, Face to Face Biometrics, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Kinetrix, NeuroDev, Inflexion Vascular, and Petal Surgical. Washington University has equity ownership of Neurolutions. The remaining authors declare no financial interest.
